Euro-Med Laboratories Phil., Inc. (PSE:EURO)
Philippines · Delayed Price · Currency is PHP 1.060
0.00 (0.00%)
At close: Jun 3, 2026
PSE:EURO Income Statement
Financials in millions PHP. Fiscal year is January - December.
Millions PHP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,841 | 6,868 | 5,796 | 5,264 | 4,224 | 3,587 | |
Revenue Growth (YoY) | 9.33% | 18.50% | 10.11% | 24.62% | 17.75% | -6.31% |
Cost of Revenue | 4,370 | 4,429 | 3,785 | 3,370 | 2,731 | 2,150 |
Gross Profit | 2,471 | 2,439 | 2,012 | 1,894 | 1,493 | 1,438 |
Selling, General & Admin | 1,532 | 1,504 | 1,312 | 1,209 | 1,025 | 991.39 |
Other Operating Expenses | 36.05 | 36.05 | 30.58 | 32.75 | 28.03 | 35.23 |
Operating Expenses | 1,568 | 1,540 | 1,343 | 1,242 | 1,053 | 1,027 |
Operating Income | 902.91 | 899.65 | 669.03 | 652.58 | 440.44 | 411.1 |
Interest Expense | -300.69 | -300.69 | -307.78 | -270.45 | -206.8 | -213.19 |
Interest & Investment Income | 5.82 | 5.82 | 2.93 | 1.29 | 0.5 | 0.7 |
Currency Exchange Gain (Loss) | 3.29 | 3.29 | 13.34 | 1.66 | 34.36 | -16.98 |
Other Non Operating Income (Expenses) | 1.46 | -16.62 | 37.48 | 0.09 | 12.88 | 5.85 |
EBT Excluding Unusual Items | 612.79 | 591.46 | 414.99 | 385.17 | 281.39 | 187.48 |
Gain (Loss) on Sale of Investments | 45.64 | 45.64 | 22.47 | 13.23 | -1.09 | 43.93 |
Pretax Income | 658.43 | 637.1 | 437.46 | 398.4 | 280.3 | 231.41 |
Income Tax Expense | 171.55 | 166.8 | 99.78 | 108.45 | 80.41 | 62.36 |
Net Income | 486.88 | 470.3 | 337.68 | 289.95 | 199.89 | 169.05 |
Net Income to Common | 486.88 | 470.3 | 337.68 | 289.95 | 199.89 | 169.05 |
Net Income Growth | 35.22% | 39.27% | 16.46% | 45.05% | 18.25% | -19.52% |
Shares Outstanding (Basic) | 4,319 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 |
Shares Outstanding (Diluted) | 4,319 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 |
EPS (Basic) | 0.11 | 0.11 | 0.08 | 0.07 | 0.05 | 0.04 |
EPS (Diluted) | 0.11 | 0.11 | 0.08 | 0.07 | 0.05 | 0.04 |
EPS Growth | 19.93% | 37.50% | 13.46% | 45.05% | 21.52% | -20.00% |
Free Cash Flow | 836.92 | 702.78 | 50.73 | 62.26 | 59.35 | 202.83 |
Free Cash Flow Per Share | 0.19 | 0.17 | 0.01 | 0.01 | 0.01 | 0.05 |
Dividend Per Share | - | - | 0.070 | 0.060 | 0.035 | 0.020 |
Dividend Growth | - | - | 16.67% | 71.43% | 75.00% | 33.33% |
Gross Margin | 36.12% | 35.52% | 34.71% | 35.98% | 35.35% | 40.08% |
Operating Margin | 13.20% | 13.10% | 11.54% | 12.40% | 10.43% | 11.46% |
Profit Margin | 7.12% | 6.85% | 5.83% | 5.51% | 4.73% | 4.71% |
Free Cash Flow Margin | 12.23% | 10.23% | 0.88% | 1.18% | 1.41% | 5.65% |
EBITDA | 1,208 | 1,225 | 928.42 | 890.72 | 664.09 | 639 |
EBITDA Margin | 17.66% | 17.84% | 16.02% | 16.92% | 15.72% | 17.81% |
D&A For EBITDA | 305.53 | 325.32 | 259.39 | 238.14 | 223.65 | 227.9 |
EBIT | 902.91 | 899.65 | 669.03 | 652.58 | 440.44 | 411.1 |
EBIT Margin | 13.20% | 13.10% | 11.54% | 12.40% | 10.43% | 11.46% |
Effective Tax Rate | 26.05% | 26.18% | 22.81% | 27.22% | 28.69% | 26.95% |